DaShenLin Pharmaceutical Group Co (SHSE:603233) Piotroski F-Score: 7 (As of Jul. 01, 2026) — 40% Above Median


SHSE:603233 DaShenLin Pharmaceutical Group Co Ltd SHSE:603233
95 GF Score
Price ¥16.20
GF Value ¥18.72
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is DaShenLin Pharmaceutical Group Co Piotroski F-Score?

DaShenLin Pharmaceutical Group Co SHSE:603233 +0.31% 95 Piotroski F-Score is 7 as of Jul. 01, 2026, which is 40% above its 10-year median of 5.00. GuruFocus rates SHSE:603233 with a GF Score™ of 95/100 and a GF Value™ of ¥18.72 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 651 Healthcare Providers & Services companies, DaShenLin Pharmaceutical Group Co ranks better than 88.94% on this metric.

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

DaShenLin Pharmaceutical Group Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for DaShenLin Pharmaceutical Group Co's Piotroski F-Score or its related term are showing as below:

SHSE:603233' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 8
Current: 7

During the past 13 years, the highest Piotroski F-Score of DaShenLin Pharmaceutical Group Co was 8. The lowest was 3. And the median was 5.

DaShenLin Pharmaceutical Group Co  (SHSE:603233) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


DaShenLin Pharmaceutical Group Co Piotroski F-Score Related Terms


DaShenLin Pharmaceutical Group Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for DaShenLin Pharmaceutical Group Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DaShenLin Pharmaceutical Group Co Piotroski F-Score Chart

DaShenLin Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 7.00 5.00 5.00 5.00

DaShenLin Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 5.00 8.00 5.00 7.00

DaShenLin Pharmaceutical Group Co Piotroski F-Score Competitor Comparison

For the Pharmaceutical Retailers subindustry, DaShenLin Pharmaceutical Group Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DaShenLin Pharmaceutical Group Co Piotroski F-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, DaShenLin Pharmaceutical Group Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where DaShenLin Pharmaceutical Group Co's Piotroski F-Score falls into.


SHSE:603233
95GF Score
DaShenLin Pharmaceutical Group Co Ltd SHSE:603233
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 338.167 + 282.831 + 154.25 + 511.142 = ¥1,286 Mil.
Cash Flow from Operations was 1142.588 + 818.691 + 1621.077 + 967.848 = ¥4,550 Mil.
Revenue was 6566.57 + 6545.673 + 7433.943 + 6973.248 = ¥27,519 Mil.
Gross Profit was 2281.426 + 2273.031 + 2450.739 + 2513.509 = ¥9,519 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(26776.018 + 25451.01 + 26081.776 + 26486.999 + 26830.178) / 5 = ¥26325.1962 Mil.
Total Assets at the begining of this year (Mar25) was ¥26,776 Mil.
Long-Term Debt & Capital Lease Obligation was ¥2,611 Mil.
Total Current Assets was ¥13,878 Mil.
Total Current Liabilities was ¥14,968 Mil.
Net Income was 259.144 + 200.529 + 56.632 + 459.998 = ¥976 Mil.

Revenue was 6593.427 + 6385.657 + 6765.538 + 6956.003 = ¥26,701 Mil.
Gross Profit was 2262.562 + 2184.919 + 2253.811 + 2432.94 = ¥9,134 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(25365.702 + 25488.502 + 25879.469 + 26439.81 + 26776.018) / 5 = ¥25989.9002 Mil.
Total Assets at the begining of last year (Mar24) was ¥25,366 Mil.
Long-Term Debt & Capital Lease Obligation was ¥4,434 Mil.
Total Current Assets was ¥13,200 Mil.
Total Current Liabilities was ¥13,660 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

DaShenLin Pharmaceutical Group Co's current Net Income (TTM) was 1,286. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

DaShenLin Pharmaceutical Group Co's current Cash Flow from Operations (TTM) was 4,550. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=1286.39/26776.018
=0.04804262

ROA (Last Year)=Net Income/Total Assets (Mar24)
=976.303/25365.702
=0.0384891

DaShenLin Pharmaceutical Group Co's return on assets of this year was 0.04804262. DaShenLin Pharmaceutical Group Co's return on assets of last year was 0.0384891. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

DaShenLin Pharmaceutical Group Co's current Net Income (TTM) was 1,286. DaShenLin Pharmaceutical Group Co's current Cash Flow from Operations (TTM) was 4,550. ==> 4,550 > 1,286 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=2611.087/26325.1962
=0.09918585

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=4433.556/25989.9002
=0.17058765

DaShenLin Pharmaceutical Group Co's gearing of this year was 0.09918585. DaShenLin Pharmaceutical Group Co's gearing of last year was 0.17058765. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=13878.16/14967.965
=0.92719084

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=13200.482/13659.582
=0.96638989

DaShenLin Pharmaceutical Group Co's current ratio of this year was 0.92719084. DaShenLin Pharmaceutical Group Co's current ratio of last year was 0.96638989. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

DaShenLin Pharmaceutical Group Co's number of shares in issue this year was 1135.872. DaShenLin Pharmaceutical Group Co's number of shares in issue last year was 1149.995. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=9518.705/27519.434
=0.34589029

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=9134.232/26700.625
=0.34209806

DaShenLin Pharmaceutical Group Co's gross margin of this year was 0.34589029. DaShenLin Pharmaceutical Group Co's gross margin of last year was 0.34209806. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=27519.434/26776.018
=1.02776425

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=26700.625/25365.702
=1.05262709

DaShenLin Pharmaceutical Group Co's asset turnover of this year was 1.02776425. DaShenLin Pharmaceutical Group Co's asset turnover of last year was 1.05262709. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+1+1+0
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

DaShenLin Pharmaceutical Group Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 7 mean?
DaShenLin Pharmaceutical Group Co (SHSE:603233) has a Piotroski F-Score of 7 as of Jul. 01, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on DaShenLin Pharmaceutical Group Co and its competitors. This is 40% above median its historical median of 5.00. Over the past decade, DaShenLin Pharmaceutical Group Co's Piotroski F-Score has ranged from 3.00 to 8.00. According to the industry distribution chart, DaShenLin Pharmaceutical Group Co ranks #72 out of 651 companies in the Healthcare Providers & Services industry, placing it in the top 11.1%.
Is DaShenLin Pharmaceutical Group Co's Piotroski F-Score too high?
DaShenLin Pharmaceutical Group Co's current Piotroski F-Score of 7 is 40% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 8.00. The Healthcare Providers & Services industry median Piotroski F-Score is 5.00. DaShenLin Pharmaceutical Group Co's value of 7 is 40% above this industry median. Based on the distribution chart, DaShenLin Pharmaceutical Group Co ranks #72 out of 651 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, DaShenLin Pharmaceutical Group Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DaShenLin Pharmaceutical Group Co's Piotroski F-Score compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, DaShenLin Pharmaceutical Group Co ranks #72 out of 651 companies for Piotroski F-Score. This places DaShenLin Pharmaceutical Group Co in the top 11% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. DaShenLin Pharmaceutical Group Co's value of 7 is 40% above this benchmark. Historically, DaShenLin Pharmaceutical Group Co's own Piotroski F-Score has ranged from 3.00 to 8.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, DaShenLin Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Healthcare Providers & Services company?
The median Piotroski F-Score among Healthcare Providers & Services companies is 5.00, based on 651 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DaShenLin Pharmaceutical Group Co's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on DaShenLin Pharmaceutical Group Co and its competitors. For the Healthcare Providers & Services industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DaShenLin Pharmaceutical Group Co's current Piotroski F-Score is 7, which is 40% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DaShenLin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co (SHSE:603233) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥18.72, compared to a current price of ¥16.20 — trading 13.5% below its estimated fair value. The current Piotroski F-Score is 7, which is 40% above median its 10-year median of 5.00 and 40% above the Healthcare Providers & Services industry median of 5.00. DaShenLin Pharmaceutical Group Co's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For DaShenLin Pharmaceutical Group Co (SHSE:603233), the current Piotroski F-Score is 7 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DaShenLin Pharmaceutical Group Co (SHSE:603233) Overvalued in 2026?

Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co stock appears to be undervalued. The current stock price of ¥16.20 is trading 13.5% below its estimated GF Value™ of ¥18.72. GuruFocus considers DaShenLin Pharmaceutical Group Co to be Modestly Undervalued.

Key valuation signals for SHSE:603233:

  • Piotroski F-Score: 7 (40% above median its 10-year median of 5.00)
  • GF Value™: ¥18.72 vs. price of ¥16.20 (13.5% below fair value)
  • GF Score™: 95/100 with 4 warning signs
  • Industry Position: 40% above the Healthcare Providers & Services median (#72 of 651)

No single metric tells the full story. See the SHSE:603233 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


DaShenLin Pharmaceutical Group Co Business Description

Address No. 410-1, Longxi Avenue, Liwan District, Guangdong Province, Guangzhou, CHN, 510000
DaShenLin Pharmaceutical Group Co Ltd is engaged in the pharmaceutical manufacturing, retail, and wholesale business. The company is based on the development of the pharmacy chain. It primarily offers Chinese herbal medicine such as antibiotics and biochemical drugs. The business activities are geographically carried out through China.
95GF Score

Get the complete analysis for SHSE:603233

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥16.20
Price
¥18.72
GF Value